Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Characterization of CNVs in a Large Cohort of VWD Patients Reveals Relationship between Disrupted Regions, Clinical Variables and Disease Type

Brooke Sadler, Pamela A Christopherson, Crystal L Perry, Daniel B. Bellissimo, Sandra L Haberichter, Gabe Haller, Lilian Antunes, Veronica H Flood, Jorge Di Paola, Robert R Montgomery, The Zimmerman Program Investigators

Blood (2022) 140 (Supplement 1): 2753–2754.

https://doi.org/10.1182/blood-2022-163383

Published: 2022

Journal Articles

Type 2M VWD Laboratory Defects More Consistent Than Bleeding Symptoms across Family Members

Laetitia Faye, Pamela A Christopherson, Sandra L Haberichter, Kenneth D. Friedman, Robert R Montgomery, Veronica H Flood

Blood (2022) 140 (Supplement 1): 8444.

https://doi.org/10.1182/blood-2022-166795

Published: 2022

Journal Articles

Bleeding Diathesis in Mice Lacking JAK2 in Platelets

Nathan Eaton, BS, Saravanan Subramaniam, PhD, Marie L Schulte, PhD, Caleb Drew, BS, David Jakab, BS, Sandra L Haberichter, PhD, Hartmut Weiler, PhD, Herve Falet, PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-138510

Published: 2020

Journal Articles

Variability in Bleeding Phenotype in Type 3 VWD Families

Pamela A Christopherson, Veronica H Flood, MD, Sandra L Haberichter, PhD, Joan Cox Gill, MD, Robert R Montgomery, MD, Zimmerman Program Investigators

Blood (2018) 132 (Supplement 1): 2466.

https://doi.org/10.1182/blood-2018-99-112961

Published: 2018

Journal Articles

Distribution of Pathogenic Variants in Von Willebrand Disease Type 2A in the American Population: Results from a National Clinical Reference Laboratory

Ruchika Sharma, MD, Juliana Perez-Botero, MD, Mia J Sullivan, BS, MB, Valerie Trapp-Stamborski, PhD, Mitchell Springer, PhD, Taquanda Gilbert, Jamie McCreery, MS, CGC, Stefanie Dugan, MS, CGC, Lijun Wang, MD PhD, Sandra L Haberichter, PhD, Kenneth Dale Friedman, MD

Blood (2018) 132 (Supplement 1): 1181.

https://doi.org/10.1182/blood-2018-99-117620

Published: 2018

Journal Articles

Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program

Veronica H Flood, MD, Pamela A Christopherson, Joan Cox Gill, MD, Kenneth Dale Friedman, MD, Sandra L Haberichter, PhD, Jorge Di Paola, MD, Paula D. James, MD, Janna M. Journeycake, MD, Steven R. Lentz, MD PhD, Cindy A. Leissinger, MD, Margaret V. Ragni, MD MPH, Madhvi Rajpurkar, MD, Jonathan C. Roberts, MD, Amy Shapiro, Robert F. Sidonio, Robert R Montgomery, MD, Thomas C. Abshire, MD

Blood (2018) 132 (Supplement 1): 979.

https://doi.org/10.1182/blood-2018-99-110650

Published: 2018

Journal Articles

Quantitative Analysis of Von Willebrand Factor (VWF) Multimers in Von Willebrand Disease (VWD) Patients Recruited through the Zimmerman Program for the Molecular and Clinical Biology of VWD

Sandra L Haberichter, PhD, Pamela A Christopherson, Veronica H Flood, MD, Joan Cox Gill, MD, Kenneth Dale Friedman, MD, Robert R. Montgomery, MD

Blood (2017) 130 (Supplement 1): 1085.

https://doi.org/10.1182/blood.V130.Suppl_1.1085.1085

Published: 2017

Journal Articles

Characterization of the Pathogenicity of Novel Sequence Variants Identified in Type 1 VWD Subjects in the Zimmerman Program for the Molecular and Clinical Biology Study

Azza Abdelaal, MD, David Jakab, Pam A Christopherson, Sandra L Haberichter, PhD

Blood (2017) 130 (Supplement 1): 20.

https://doi.org/10.1182/blood.V130.Suppl_1.20.20

Published: 2017

Journal Articles

Genotype-Phenotype Relationship and the Role of Alloantibodies in Type 3 VWD in the Zimmerman Program

Pamela A Christopherson, Crystal L Perry, Daniel B. Bellissimo, PhD, Veronica H Flood, MD, Joan Cox Gill, MD, Sandra L Haberichter, PhD, Robert R. Montgomery, MD, Zimmerman Program Investigators

Blood (2017) 130 (Supplement 1): 19.

https://doi.org/10.1182/blood.V130.Suppl_1.19.19

Published: 2017

Journal Articles

Identification of Copy Number Variants in Type 1 and Type 3 VWD by aCGH in the Zimmerman Program

Pamela A Christopherson, Rupa A Udani, PhD, Crystal Perry, BS, Daniel B Bellissimo, PhD, Sandra L Haberichter, PhD, Veronica H Flood, MD, Kenneth D Friedman, MD, Joan Cox Gill, MD, Robert R. Montgomery, MD, Zimmerman Program Investigators

Blood (2016) 128 (22): 872.

https://doi.org/10.1182/blood.V128.22.872.872

Published: 2016

Journal Articles

Von Willebrand Factor (VWF) Propeptide and Factor VIII (FVIII) Levels Identify the Contribution of Decreased Synthesis and/or Increased Clearance Mechanisms in the Pathogenesis of Type 1 Von Willebrand Disease (VWD) in the Zimmerman Program

Sandra L Haberichter, PhD, Pamela A Christopherson, Veronica H Flood, MD, Joan Cox Gill, MD, Kenneth D Friedman, MD, Robert R. Montgomery, MD

Blood (2016) 128 (22): 874.

https://doi.org/10.1182/blood.V128.22.874.874

Published: 2016

Journal Articles

Expression of Sequence Variants Identified in Type 1 VWD Subjects in the Zimmerman Program Study Reveals Defects in VWF Secretion and Multimerization

Azza Abdelaal, MD M.S., David Jakab, B.S., Pamela A Christopherson, Robert R Montgomery, MD, Sandra L Haberichter, PhD

Blood (2016) 128 (22): 1398.

https://doi.org/10.1182/blood.V128.22.1398.1398

Published: 2016

Journal Articles

Humanized Von Willebrand Factor-Glycoprotein Ibα Interaction in Mouse Models of Hemostasis and Thrombosis

Sachiko Kanaji, MD PhD, Jennifer N Orje, Yuichi Kamikubo, PhD, Taisuke Kanaji, MD PhD, Jeremy Mattson, Alessandro Zarpellon, PhD, Scot A. Fahs, Rashmi Sood, PhD, Sandra L Haberichter, PhD, Zaverio M. Ruggeri, MD, Robert R Montgomery, MD

Blood (2016) 128 (22): 558.

https://doi.org/10.1182/blood.V128.22.558.558

Published: 2016

Journal Articles

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States

Blood (2016) 127 (20): 2481–2488.

https://doi.org/10.1182/blood-2015-10-673681

Published: 2016

Includes: Supplemental data

Journal Articles

Prevalence of Low VWF, VWD, and Isolated Collagen Binding Defects in Subjects Undergoing Evaluation for VWD

Sandra L Haberichter, PhD, Tricia L Slobodianuk, Andrew Podd, Kenneth D Friedman, MD, Veronica H Flood, MD

Blood (2015) 126 (23): 1090.

https://doi.org/10.1182/blood.V126.23.1090.1090

Published: 2015

Journal Articles

Domain Distribution of Type 1 VWD Sequence Variants and Impact on Clinical and Laboratory Phenotype in the Zimmerman Program

Pamela A Christopherson, Veronica H Flood, MD, Sandra L Haberichter, PhD, Daniel B Bellissimo, PhD, Kenneth D Friedman, MD, Joan Cox Gill, MD, Rupa A Udani, PhD, Robert R Montgomery, MD

Blood (2015) 126 (23): 758.

https://doi.org/10.1182/blood.V126.23.758.758

Published: 2015

Journal Articles

von Willebrand factor propeptide: biology and clinical utility

Sandra L. Haberichter

Blood (2015) 126 (15): 1753–1761.

https://doi.org/10.1182/blood-2015-04-512731

Published: 2015

Journal Articles

VWF propeptide in defining VWD subtypes

Sandra L. Haberichter

Blood (2015) 125 (19): 2882–2883.

https://doi.org/10.1182/blood-2015-03-629832

Published: 2015

Journal Articles

Crucial role for the VWF A1 domain in binding to type IV collagen

Veronica H. Flood, Abraham C. Schlauderaff, Sandra L. Haberichter, Tricia L. Slobodianuk, Paula M. Jacobi, Daniel B. Bellissimo, Pamela A. Christopherson, Kenneth D. Friedman, Joan Cox Gill, Raymond G. Hoffmann, Robert R. Montgomery, the Zimmerman Program Investigators

Blood (2015) 125 (14): 2297–2304.

https://doi.org/10.1182/blood-2014-11-610824

Published: 2015

Journal Articles

A Native Whole Blood Thrombin Generation Assay Allows Discrimination of Whole Blood Samples with FVIII Levels below 1%

Christina K Baumgartner, Jonathan C Roberts, Paula M Jacobi, Sandra L Haberichter, Qizhen Shi, Robert R. Montgomery, MD

Blood (2014) 124 (21): 4215.

https://doi.org/10.1182/blood.V124.21.4215.4215

Published: 2014

NARROW

Characterization of CNVs in a Large Cohort of VWD Patients Reveals Relationship between Disrupted Regions, Clinical Variables and Disease Type

Type 2M VWD Laboratory Defects More Consistent Than Bleeding Symptoms across Family Members

Bleeding Diathesis in Mice Lacking JAK2 in Platelets

Variability in Bleeding Phenotype in Type 3 VWD Families

Distribution of Pathogenic Variants in Von Willebrand Disease Type 2A in the American Population: Results from a National Clinical Reference Laboratory

Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program

Quantitative Analysis of Von Willebrand Factor (VWF) Multimers in Von Willebrand Disease (VWD) Patients Recruited through the Zimmerman Program for the Molecular and Clinical Biology of VWD

Characterization of the Pathogenicity of Novel Sequence Variants Identified in Type 1 VWD Subjects in the Zimmerman Program for the Molecular and Clinical Biology Study

Genotype-Phenotype Relationship and the Role of Alloantibodies in Type 3 VWD in the Zimmerman Program

Identification of Copy Number Variants in Type 1 and Type 3 VWD by aCGH in the Zimmerman Program

Von Willebrand Factor (VWF) Propeptide and Factor VIII (FVIII) Levels Identify the Contribution of Decreased Synthesis and/or Increased Clearance Mechanisms in the Pathogenesis of Type 1 Von Willebrand Disease (VWD) in the Zimmerman Program

Expression of Sequence Variants Identified in Type 1 VWD Subjects in the Zimmerman Program Study Reveals Defects in VWF Secretion and Multimerization

Humanized Von Willebrand Factor-Glycoprotein Ibα Interaction in Mouse Models of Hemostasis and Thrombosis

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States

Prevalence of Low VWF, VWD, and Isolated Collagen Binding Defects in Subjects Undergoing Evaluation for VWD

Domain Distribution of Type 1 VWD Sequence Variants and Impact on Clinical and Laboratory Phenotype in the Zimmerman Program

von Willebrand factor propeptide: biology and clinical utility

VWF propeptide in defining VWD subtypes

Crucial role for the VWF A1 domain in binding to type IV collagen

A Native Whole Blood Thrombin Generation Assay Allows Discrimination of Whole Blood Samples with FVIII Levels below 1%

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only